Candel Therapeutics (CADL) Total Current Liabilities (2020 - 2025)

Candel Therapeutics has disclosed Total Current Liabilities across 6 years of filings, most recently posting $9.0 million for Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $9.0 million, down 76.03% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.0 million (down 76.03% YoY), and the FY2025 annual result was $9.0 million, down 76.03% from the prior year.
• Total Current Liabilities came in at $9.0 million for Q4 2025 at Candel Therapeutics, down from $10.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $37.5 million in Q4 2024 to a low of $4.4 million in Q3 2021.
• The 5-year median for Total Current Liabilities is $9.0 million (2025), against an average of $11.1 million.
• Across the five-year window, Total Current Liabilities soared 164.59% in 2024 and slumped 76.03% in 2025, its largest moves.
• Candel Therapeutics' Total Current Liabilities stood at $5.4 million in 2021, then grew by 4.72% to $5.6 million in 2022, then jumped by 152.61% to $14.2 million in 2023, then surged by 164.59% to $37.5 million in 2024, then plunged by 76.03% to $9.0 million in 2025.
• The last three Total Current Liabilities figures came in at $9.0 million (Q4 2025), $10.9 million (Q3 2025), and $14.7 million (Q2 2025), per Business Quant data.